Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer
This is the first report exploring the efficacy and safety of treating patients concurrently with Cadonilimab plus bevacizumab or anlotinib with heavily pretreated r/mCC. The findings suggest that this regimen might be potentially efficacious and safe with relatively manageable toxicity. Further trials with a control arm are required to validate our findings.
Authors
- Yipeng Song
- Y. Li (ORCID: https://orcid.org/0009-0003-5783-3935)
- Cuicui Meng
- Zhou Fang (ORCID: https://orcid.org/0000-0002-5231-6539)
- Danial F. Naseem (ORCID: https://orcid.org/0000-0002-1247-6140)
- Yin Wang (ORCID: https://orcid.org/0000-0001-8586-9714)
- Shu-Shu Liu
- Ying Zuo (ORCID: https://orcid.org/0000-0001-5454-2006)
Institutions
- Qingdao University (CN)
- The University of Texas MD Anderson Cancer Center (US)
- National Health and Family Planning Commission (CN)
- Yuhuangding Hospital (CN)
- Yantaishan Hospital (CN)
- Weifang Maternity and Child Care Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.3389/fonc.2025.1614434
- Citations
- 1
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 2.01